Pedro L Vera Selected Research

Inflammation (Inflammations)

4/2024	MIF-Modulated Spinal Proteins Associated with Persistent Bladder Pain: A Proteomics Study.
3/2019	MIF mediates bladder pain, not inflammation, in cyclophosphamide cystitis.
10/2018	Protease activated-receptor 4 activation as a model of persistent bladder pain: Essential role of macrophage migration inhibitory factor and high mobility group box 1.
12/2017	Macrophage migration inhibitory factor mediates protease-activated receptor 4-induced bladder pain through urothelial high mobility group box 1.
5/2017	Disulfide high mobility group box-1 causes bladder pain through bladder Toll-like receptor 4.
1/2016	Protease-Activated Receptor 4 Induces Bladder Pain through High Mobility Group Box-1.
1/2015	Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain.
12/2010	Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation.
11/2010	Antagonism of macrophage migration inhibitory factor decreases cyclophosphamide cystitis in mice.
4/2010	Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro L Vera Research Topics

Disease

22	Inflammation (Inflammations) 04/2024 - 08/2003
12	Pain (Aches) 04/2024 - 01/2015
7	Cystitis 03/2019 - 08/2003
7	Hypersensitivity (Allergy) 01/2019 - 04/2004
6	Hyperalgesia 04/2024 - 10/2004
6	Neoplasms (Cancer) 10/2011 - 07/2004
4	Edema (Dropsy) 05/2017 - 01/2004
3	Prostatic Neoplasms (Prostate Cancer) 05/2011 - 07/2005
2	Interstitial Cystitis (Interstitial Cystitis, Chronic) 03/2019 - 01/2018
2	Neuralgia (Stump Neuralgia) 03/2019 - 01/2019
2	Urinary Bladder Neoplasms (Bladder Cancer) 04/2010 - 07/2004
2	Adenocarcinoma 07/2005 - 07/2004
2	Neurogenic Inflammation 10/2004 - 04/2004
1	Skin Neoplasms (Skin Cancer) 01/2019
1	Carcinogenesis 04/2010
1	Body Weight (Weight, Body) 07/2008
1	Urinary Tract Infections (Urinary Tract Infection) 04/2006
1	Abnormal Reflex (Hyperreflexia) 12/2004
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 04/2004
1	Ganglion Cysts (Ganglion) 01/2004

Drug/Important Bio-Agent (IBA)

31	Macrophage Migration-Inhibitory FactorsIBA 01/2023 - 08/2003
14	CytokinesIBA 12/2010 - 08/2003
9	Proteins (Proteins, Gene)FDA Link 04/2024 - 08/2003
7	HMGB1 Protein (HMG1)IBA 01/2023 - 01/2016
6	Peptide Hydrolases (Proteases)FDA Link 04/2024 - 09/2006
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2019 - 01/2008
5	Substance PIBA 06/2009 - 04/2004
4	Peptides (Polypeptides)IBA 01/2024 - 01/2016
4	protease-activated receptor 4IBA 01/2019 - 01/2016
4	Messenger RNA (mRNA)IBA 11/2010 - 08/2003
3	Butylated Hydroxyanisole (BHA)IBA 04/2024 - 01/2022
3	DisulfidesIBA 01/2023 - 05/2017
3	macrophage migration inhibitory factor receptorIBA 01/2021 - 05/2008
3	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2019 - 01/2016
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2004 - 08/2003
2	Thrombin FDA Link 12/2010 - 04/2010
2	Nerve Growth Factor (NGF)IBA 11/2010 - 10/2004
2	LigandsIBA 01/2008 - 12/2006
2	alpha 1-inhibitor 3IBA 09/2006 - 07/2005
1	salicylhydroxamic acid (SHAM)IBA 04/2024
1	Immunoglobulin G (IgG)IBA 04/2024
1	MetallothioneinIBA 01/2024
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2019
1	Phosphodiesterase 5 InhibitorsIBA 01/2019
1	Analgesics (Analgesic Drugs)IBA 01/2019
1	MIF098IBA 10/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Proteinase-Activated ReceptorsIBA 12/2017
1	Toll-Like Receptor 4IBA 05/2017
1	FPS-ZM1IBA 05/2017
1	ethyl 6- (N- (2- chloro- 4- fluorophenyl)sulfamoyl)cyclohex- 1- ene- 1- carboxylateIBA 05/2017
1	Sulfhydryl Compounds (Thiols)IBA 05/2017
1	ChromatinIBA 01/2016
1	Carrier Proteins (Binding Protein)IBA 01/2016
1	plerixafor FDA Link 01/2015
1	Atrial Natriuretic Factor (ANF)IBA 05/2011
1	Hormones (Hormone)IBA 05/2011
1	Natriuretic PeptidesIBA 05/2011
1	atrial natriuretic factor receptor AIBA 05/2011
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 11/2010
1	Endoplasmic Reticulum Chaperone BiPIBA 06/2009
1	Phentolamine (Z-Max)FDA LinkGeneric 07/2008
1	Atropine FDA LinkGeneric 07/2008
1	Lidocaine (Xylocaine)FDA LinkGeneric 07/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 07/2008
1	Hexamethonium (Hexamethonium Bromide)IBA 07/2008
1	Propranolol (Inderal)FDA LinkGeneric 07/2008
1	Chemokine ReceptorsIBA 01/2008
1	AndrogensIBA 12/2006
1	Formaldehyde (Formol)FDA Link 12/2004
1	Phenobarbital (Luminal)FDA Link 10/2004
1	NeuropeptidesIBA 04/2004
1	EndotoxinsIBA 01/2004

Therapy/Procedure

4	Intravesical Administration 01/2024 - 05/2017
1	Aftercare (After-Treatment) 01/2015
1	Therapeutics 12/2006